Rivia Secures €13 Million in Series A Funding
Rivia, a Zurich-based company specializing in AI-driven analytics for biotech clinical trials, has announced a successful Series A funding round, raising €13 million. The funding round was led by Earlybird, with additional backing from Defiant, Speedinvest, Amino Collective, and Nina Capital.
Founded by Erik Scalfaro and Tiago Kieliger, who serve as CEO and CTO respectively, Rivia focuses on integrating fragmented trial data into a unified platform. This approach aims to provide actionable insights, helping biotech companies streamline their clinical trial operations and unlock new therapeutic possibilities.
Strategic Use of Funds
The newly acquired funds will be directed towards expanding Rivia's team and scaling their product development efforts. Additionally, the company plans to grow its international presence, particularly targeting the US market. The expansion will involve deploying AI-driven agents to enhance clinical trial processes, aiming to reduce human effort and improve trial execution speed and precision.
Addressing Industry Challenges
Rivia's platform is designed to tackle the complexities associated with modern clinical trials, which often involve fragmented systems and large volumes of data. By creating a unified data layer and ontology-driven infrastructure, Rivia enables biotech firms to conduct global trials more efficiently. This approach not only helps in identifying potential issues that could cause costly delays but also provides earlier insights into patient outcomes.
A Structural Advantage
CEO Erik Scalfaro highlighted the company's strategic development approach, stating: "Two years ago, we made a deliberate decision. We started with the scaffolding, building the foundational data engine before turning to agents. Today, that vertical sequence of data engine to agents gives us a structural advantage." This method has allowed Rivia to support biotech companies in executing global trials with measurable results.
As the company continues to grow, the ontology library within their platform compounds, enhancing the system's performance and insights over time. Rivia's commitment to improving clinical trial efficiency positions it as a key player in the biotech industry, helping bring new drugs to market more effectively.
With the completion of this funding round, Rivia is well-positioned to expand its capabilities and further solidify its presence in the global biotech ecosystem.